Northwest Biotherapeutics reported $87.9M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Agenus USD 249.24M 74.25M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Celldex Therapeutics USD 51.47M 481K Mar/2026
Eisai JPY 340.25B 47.42B Mar/2026
Infinity Pharmaceuticals USD 12.06M 775K Jun/2023
Merck USD 26.94B 1.38B Mar/2026
Northwest Biotherapeutics USD 87.9M 3.98M Sep/2025
Pfizer USD 34.35B 2.64B Mar/2026
Plus Therapeutics USD 7.96M 4.36M Mar/2026
Roche Holding CHF 28B 421M Dec/2025